NasdaqCM:NKTRPharmaceuticals
A Look At Nektar Therapeutics (NKTR) Valuation As Rezpegaldesleukin Data Heads To Major Dermatology Meeting
Nektar Therapeutics (NKTR) is back in focus after announcing that Phase 2b data for its lead candidate, rezpegaldesleukin, in atopic dermatitis and alopecia areata will be featured in two oral presentations at the 2026 American Academy of Dermatology meeting.
See our latest analysis for Nektar Therapeutics.
The rezpegaldesleukin update lands after a sharp turnaround in sentiment, with a 90 day share price return of 67.21% and a 1 year total shareholder return of almost 5x despite a weak 2025...